Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis profile to understand mechanisms activated by FDA molecules that overcome the ATP7B mediated resistance to cisplatin in ovarian cancer IGROV-CP20 cells.

ABSTRACT: To understand whether treatments with FDA drugs Trelmisartan, Tranilast or Amphotericin B were able to downregulate pathways important to overcome resistance to cisplatin in ovarian cancer cells IGROV-0CP20 we cemployed Quant-seq Analysis.Transcriptome of the of IGROV-CP20 cells treated with cisplatin and each of the three FDA molecules were compared with untreated cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE134029 | GEO | 2020/04/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptome analysis profile to understand mechanisms activated by FDA molecules that overcome the ATP7B mediated resistance to cisplatin in ovarian cancer IGROV-CP20 cells.

Project description:Transcriptome analysis profile to understand mechanisms activated by FDA molecules that overcome the ATP7B mediated resistance to cisplatin in ovarian cancer IGROV-CP20 cells.

| PRJNA553517 | ENA

FDA CVM

Project description:FDA CVM

| PRJNA311513 | ENA

Gene expression profiling after RNA interference of CXCR4 in human ovarian cancer cell line IGROV-1.

Project description:In the past three years the role of inflammatory cytokines and chemokines in tumour promotion and progression has been intensively studied. The chemokine receptor CXCR4 and its ligand CXCL12 are commonly expressed in malignant cells from primary tumours, metastases and also in malignant cell lines. To investigate the biological significance of this receptor/ligand pair, we knocked-down CXCR4 expression in ovarian cancer cell line IGROV-1 using shRNA, and established stable cell lines. Using Affymetrix microarrays we compared in vitro gene expression in parental IGROV-1 and IGROV-Mock cells with two clones of IGROV-shCXCR4 cells. Gene Set Enrichment Analysis (GSEA) of those genes which were altered by RNA interference of CXCR4 revealed evidence for a cell autonomous signaling network involving CXCR4, TNF-a, IL6 and Notch pathways in ovarian cancer cells. Keywords: Affymetrix GeneChip Human Genome U133Plus 2.0

2008-11-29 | GSE13763 | GEO

CRISPR screens by human betacoronaviruses SARS-CoV-2 and HCoV-OC43 using IGROV-1 cells

Project description:The emergence of novel betacoronaviruses has posed significant financial and human health burdens, necessitating the development of appropriate tools to combat future outbreaks. In this study, we have characterized a human cell line, IGROV-1, as a robust tool to detect, propagate, and titrate betacoronavirus SARS-CoV-2 and HCoV-OC43. IGROV-1 cells can be used for serological assays, antiviral drug testing, and isolating SARS-CoV-2 variants from patient samples. Using time-course transcriptomics, we confirmed that IGROV-1 cells exhibit a robust innate immune response upon SARS-CoV-2 infection, recapitulating the response previously observed in primary human nasal epithelial cells. We performed genome-wide CRISPR knockout genetic screens in IGROV-1 cells and identified Aryl hydrocarbon receptor (AHR) as a critical host dependency factor for both SARS-CoV-2 and HCoV-OC43. Using DiMNF, a small molecule inhibitor of AHR, we observed that the drug selectively inhibits HCoV-OC43 infection but not SARS-CoV-2. Transcriptomic analysis in primary normal human bronchial epithelial cells revealed that DiMNF blocks HCoV-OC43 infection via basal activation of innate immune responses. Our findings highlight the potential of IGROV-1 cells as a valuable diagnostic and research tool to combat betacoronavirus diseases.

2023-09-19 | GSE237122 | GEO

Identification of AHR as a pro-viral host factor of human betacoronaviruses SARS-CoV-2 using IGROV-1 cells

2023-09-18 | GSE237121 | GEO

Gene expression profiling after RNA interference of CXCR4 in human ovarian cancer cell line IGROV-1.

Project description:In the past three years the role of inflammatory cytokines and chemokines in tumour promotion and progression has been intensively studied. The chemokine receptor CXCR4 and its ligand CXCL12 are commonly expressed in malignant cells from primary tumours, metastases and also in malignant cell lines. To investigate the biological significance of this receptor/ligand pair, we knocked-down CXCR4 expression in ovarian cancer cell line IGROV-1 using shRNA, and established stable cell lines. Using Affymetrix microarrays we compared in vitro gene expression in parental IGROV-1 and IGROV-Mock cells with two clones of IGROV-shCXCR4 cells. Gene Set Enrichment Analysis (GSEA) of those genes which were altered by RNA interference of CXCR4 revealed evidence for a cell autonomous signaling network involving CXCR4, TNF-a, IL6 and Notch pathways in ovarian cancer cells. Experiment Overall Design: The Affymetrix GeneChip Human Genome U133Plus 2.0 arrays were used to define gene expression profiles in each cell line.

2009-01-13 | E-GEOD-13763 | biostudies-arrayexpress

FDA-CDC Antimicrobial Resistance Bank

Project description:FDA-CDC Antimicrobial Resistance Bank

| PRJNA294416 | ENA

Gene expression profiling of anti-human VEGF-treated tumor xenografts formed by IGROV-1 or SKOV3 cells

Project description:This microarray experiment was designed to identify genes and pathways modulated in ovarian cancer xenografts treated with anti-human VEGF mAb (Bevacizumab). Tumors were established in NOD/SCID mice by s.c. injection of human ovarian cancer cells (IGROV-1 and SKOV3). Mice were treated with the anti-VEGF monoclonal antibody Bevacizumab or with PBS (control). Total RNA was extracted from tumor samples and hybridized on Affymetrix GeneChip™ PrimeView™ Human Gene Expression Arrays. Each sample was derived from a different mouse (n=5 mice/group). In order to evaluate the effects of the anti-human VEGF mAb in the two models, expression data of IGROV-1 and SKOV3 derived tumors were normalized and analyzed separately. Raw microarray data, preprocessed data matrix and results of differential expression analysis are available together with the applied protocols.

2019-12-16 | E-MTAB-7683 | biostudies-arrayexpress

FDA/CDC Antimicrobial Resistant Isolate Bank

Project description:FDA/CDC Isolate Bank Genome Sequencing

| PRJNA316321 | ENA

GNPS-FDA(Selleckchemicals)_NIHcollectionIandII

Project description:http://www.nihclinicalcollection.com/index.php http://www.selleckchem.com/screening/fda-approved-drug-library.html#chemicallib

2014-03-19 | MSV000078567 | GNPS

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data